These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35236568)

  • 1. Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial.
    Schiza A; Thurfjell V; Stenmark Tullberg A; Olofsson H; Lindberg A; Holmberg E; Bremer T; Micke P; Karlsson P; Wärnberg F; Strell C
    Eur J Cancer; 2022 Jun; 168():128-137. PubMed ID: 35236568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS).
    Darvishian F; Ozerdem U; Adams S; Chun J; Pirraglia E; Kaplowitz E; Guth A; Axelrod D; Shapiro R; Price A; Troxel A; Schnabel F; Roses D
    Ann Surg Oncol; 2019 Oct; 26(10):3337-3343. PubMed ID: 31240590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.
    Pruneri G; Lazzeroni M; Bagnardi V; Tiburzio GB; Rotmensz N; DeCensi A; Guerrieri-Gonzaga A; Vingiani A; Curigliano G; Zurrida S; Bassi F; Salgado R; Van den Eynden G; Loi S; Denkert C; Bonanni B; Viale G
    Ann Oncol; 2017 Feb; 28(2):321-328. PubMed ID: 28426105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prognostic and predictive computational pathology immune signature for ductal carcinoma in situ: retrospective results from a cohort within the UK/ANZ DCIS trial.
    Li H; Aggarwal A; Toro P; Fu P; Badve SS; Cuzick J; Madabhushi A; Thorat MA
    Lancet Digit Health; 2024 Aug; 6(8):e562-e569. PubMed ID: 38987116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial.
    Strell C; Folkvaljon D; Holmberg E; Schiza A; Thurfjell V; Karlsson P; Bergh J; Bremer T; Akslen LA; Wärnberg F; Östman A
    Clin Cancer Res; 2021 Jun; 27(12):3469-3477. PubMed ID: 33952629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.
    Toss MS; Miligy I; Al-Kawaz A; Alsleem M; Khout H; Rida PC; Aneja R; Green AR; Ellis IO; Rakha EA
    Mod Pathol; 2018 Aug; 31(8):1226-1236. PubMed ID: 29559742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour-infiltrating lymphocytes in ductal carcinoma in situ (DCIS)-assessment with three different methodologies and correlation with Oncotype DX DCIS Score.
    Komforti M; Badve SS; Harmon B; Lo Y; Fineberg S
    Histopathology; 2020 Nov; 77(5):749-759. PubMed ID: 32557780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Touching tumour-infiltrating lymphocytes in low-risk ductal carcinoma in situ (DCIS) correlate with upgrading to high-grade DCIS.
    Khoury T; Quinn M; Tian W; Yan L; Zhan H
    Histopathology; 2022 Jan; 80(2):291-303. PubMed ID: 34379814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
    Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
    Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher densities of tumour-infiltrating lymphocytes and CD4
    Thike AA; Chen X; Koh VCY; Binte Md Nasir ND; Yeong JPS; Bay BH; Tan PH
    Histopathology; 2020 May; 76(6):852-864. PubMed ID: 31883279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast.
    Lazzeroni M; DeCensi A; Guerrieri-Gonzaga A; Pagan E; Bagnardi V; Macis D; Serrano D; Vingiani A; Bonizzi G; Barberis M; Pruneri G; Wagner S; Gandini S; Viale G; Bonanni B
    Mod Pathol; 2020 Jun; 33(6):1065-1077. PubMed ID: 31925342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.
    Schmitz RSJM; van den Belt-Dusebout AW; Clements K; Ren Y; Cresta C; Timbres J; Liu YH; Byng D; Lynch T; Menegaz BA; Collyar D; Hyslop T; Thomas S; Love JK; Schaapveld M; Bhattacharjee P; Ryser MD; Sawyer E; Hwang ES; Thompson A; Wesseling J; Lips EH; Schmidt MK;
    BMJ; 2023 Oct; 383():e076022. PubMed ID: 37903527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative radiotherapy after DCIS: Useful for whom?
    Karlsson P
    Breast; 2017 Aug; 34 Suppl 1():S43-S46. PubMed ID: 28663003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.
    Solin LJ; Gray R; Hughes LL; Wood WC; Lowen MA; Badve SS; Baehner FL; Ingle JN; Perez EA; Recht A; Sparano JA; Davidson NE
    J Clin Oncol; 2015 Nov; 33(33):3938-44. PubMed ID: 26371148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
    Vrieling C; van Werkhoven E; Maingon P; Poortmans P; Weltens C; Fourquet A; Schinagl D; Oei B; Rodenhuis CC; Horiot JC; Struikmans H; Van Limbergen E; Kirova Y; Elkhuizen P; Bongartz R; Miralbell R; Morgan DA; Dubois JB; Remouchamps V; Mirimanoff RO; Hart G; Collette S; Collette L; Bartelink H;
    JAMA Oncol; 2017 Jan; 3(1):42-48. PubMed ID: 27607734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast.
    Jia H; Zhao P; Chen Z; Wang G; Dong X; Xing X; Tan X; Wang C
    Breast Cancer Res Treat; 2022 May; 193(1):111-120. PubMed ID: 35260954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective use of whole breast radiotherapy after breast conserving surgery for invasive breast cancer and DCIS.
    Skandarajah AR; Bruce Mann G
    Surgeon; 2013 Oct; 11(5):278-85. PubMed ID: 23632044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
    Solin LJ; Gray R; Baehner FL; Butler SM; Hughes LL; Yoshizawa C; Cherbavaz DB; Shak S; Page DL; Sledge GW; Davidson NE; Ingle JN; Perez EA; Wood WC; Sparano JA; Badve S
    J Natl Cancer Inst; 2013 May; 105(10):701-10. PubMed ID: 23641039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
    Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
    J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local treatment options for young women with ductal carcinoma in situ: A systematic review and meta-analysis comparing breast conserving surgery with or without adjuvant radiotherapy, and mastectomy.
    Chien JC; Liu WS; Huang WT; Shih LC; Liu WC; Chen YC; Chou KJ; Shiue YL; Lin PC
    Breast; 2022 Jun; 63():29-36. PubMed ID: 35299032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.